Clinical Trial Update: Clinical Study of Camrelizumab Combined With SOX in the Adjuvant Treatment of Advanced Gastric Adenocarcinoma or Gastric Esophageal Junction Adenocarcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating camrelizumab combined with SOX as adjuvant treatment for advanced gastric adenocarcinoma or gastroesophageal junction adenocarcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Adenocarcinoma
• Gastric Cancer
• Gastroesophageal Junction Cancer

Drugs mentioned

• Camrelizumab (camrelizumab)

Snippet

Sponsor: The Second Affiliated Hospital of Shandong First Medical University | Conditions: Gastric Cancer | Phase 2 | Status: UNKNOWN